Vimarsana
Biggest News Aggregation in the World

Based Compensation Expense News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Based Compensation Expense. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Based Compensation Expense Today - Breaking & Trending Today

Rimini Street Announces Fiscal First Quarter 2024 Financial and Operating Results - Vimarsana News

Rimini Street Announces Fiscal First Quarter 2024 Financial and Operating Results

Rimini Street, Inc. , a global provider of end-to-end enterprise software support, products and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and...

MACOM Reports Fiscal Second Quarter 2024 Financial Results - Vimarsana News

MACOM Reports Fiscal Second Quarter 2024 Financial Results

MACOM Technology Solutions Holdings, Inc. , a leading supplier of semiconductor products, today announced its financial results for its fiscal second quarter ended March 29, 2024. Second Quarter...

Dayforce : First Quarter 2024 Press Release - Vimarsana News

Dayforce : First Quarter 2024 Press Release

Dayforce Reports First Quarter 2024 Results1 Dayforce® recurring revenue of $337.2 million, up 24.3%, and excluding float revenue, up 23.0% ...

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results - Vimarsana News

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results

Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ technology, today announced business updates and financial results for the...

ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates - Vimarsana News

ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q sales grew sequentially in both academic and community settings Focused pipeline progressing with continued LOTIS-7 dose escalation, screening patients for ADCT-601 targeting AXL in pancreatic cancer, and advancing differentiated solid tumor research platform FY 2023 operating expenses decreased 21%1 year-over-year due to portfolio prioritization and operational efficiencie

Source: yahoo.com